Bavarian Nordic A/S Receives IMVAMUNE Smallpox Vaccine Order from Biomedical Advanced Research and Development Authority; Confirms FY 2013 Revenue and Result before Tax Guidance

Tuesday, 16 Apr 2013 11:01am EDT 

Bavarian Nordic A/S announced that BARDA (Biomedical Advanced Research and Development Authority), a division of the U.S. Department of Health & Human Services (HHS), has awarded the Company a contract valued at up to USD 228 million for the continued supply of the Company's IMVAMUNE smallpox vaccine. The first USD 110 million of the new order is secured, and the remaining portion will be secured based on availability of funds in 2014. Under the agreement, payments of additional USD 37 million will be received, associated with the delivery of the original 20 million dose order. Additionally, Bavarian Nordic A/S announced that its fiscal year 2013 revenue guidance remains unchanged at the level of DKK 1,100 million. The Company also continues to expect break-even result before tax for the fiscal year 2013. The cash preparedness at year-end is expected to be roughly DKK 600 million. According to I/B/E/S Estimates analysts on average are expecting the Company to report revenue of DKK 1,095.80 million for the fiscal year 2013. 

Company Quote

5.0 +2.65%
24 Oct 2014